Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
received:
29
09
2023
accepted:
10
01
2024
revised:
09
01
2024
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
25
1
2024
Statut:
aheadofprint
Résumé
Letermovir prophylaxis revolutionized the approach to Cytomegalovirus infection in adult hematopoietic stem cell transplant (HCT), while data in pediatric setting are still lacking. We retrospectively analyzed 87 HCT children transplanted in 11 AIEOP centers receiving letermovir as off-label indication between January 2020 and November 2022. Letermovir was used as primary, secondary prophylaxis or CMV treatment in 39, 26 and 22 cases, respectively; no discontinuation due to toxicity was reported. Median duration was 100 days (14-256) for primary and 96 days (8-271) for secondary prophylaxis, respectively. None of the patients experienced CMV-clinically significant reactivation during Letermovir primary prophylaxis; one patient developed breakthrough infection during secondary prophylaxis, and 10 and 1 patient experienced asymptomatic CMV-reactivation and CMV-primary infection after drug discontinuation, respectively. Median duration of letermovir in CMV treatment was 40 days (7-134), with 4/22 patients suffering CMV-pneumonia, with an overall response rate of 86.4%. With a median follow-up of 10.7 months (8.2-11.8), estimated 1-year overall survival was 86%; no CMV-related deaths were reported in prophylaxis groups. This is the largest report on Letermovir use in pediatric HCT; real-life data confirm an excellent toxicity profile, with high efficacy as CMV prophylaxis; results in CMV-infection treatment should be investigated in larger, prospective trials.
Identifiants
pubmed: 38272999
doi: 10.1038/s41409-024-02209-2
pii: 10.1038/s41409-024-02209-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119–27.
pubmed: 26947200
pmcid: 4914379
doi: 10.1016/S2352-3026(15)00289-6
Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transpl. 2010;16:1309–14.
doi: 10.1016/j.bbmt.2010.03.020
Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Ann Hematol. 2019;98:1755–63.
pubmed: 30993417
doi: 10.1007/s00277-019-03669-z
Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis. 2021;13:123–40.
pubmed: 34305463
pmcid: 8294301
doi: 10.1007/s40506-021-00253-w
Heston SM, Young RR, Tanaka JS, Jenkins K, Vinesett R, Saccoccio FM, et al. Risk factors for CMV viremia and treatment-associated adverse events among pediatric hematopoietic stem cell transplant recipients. Open Forum Infect Dis. 2022;9:ofab639.
pubmed: 35111869
doi: 10.1093/ofid/ofab639
Thomas G, Guy H, Nicole E, Helga R-S, Holger Z, Peter L. The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase. J Virol. 2011;85:10884–93.
doi: 10.1128/JVI.05265-11
Griffiths P, Lumley S. Cytomegalovirus. Curr Opin Infect Dis. 2014;27:554–9.
pubmed: 25304390
doi: 10.1097/QCO.0000000000000107
Derigs P, Radujkovic A, Schubert M-L, Schnitzler P, Schöning T, Müller-Tidow C, et al. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Ann Hematol. 2021;100:2087–93.
pubmed: 33270162
doi: 10.1007/s00277-020-04362-2
Chemaly RF, Ullmann AJ, Ehninger G. CMV prophylaxis in hematopoietic-cell transplantation. N. Engl J Med. 2014;371:576–7.
pubmed: 25099585
doi: 10.1056/NEJMc1406756
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl J Med. 2017;377:2433–44.
pubmed: 29211658
doi: 10.1056/NEJMoa1706640
Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transpl. 2021;56:853–62.
doi: 10.1038/s41409-020-01082-z
Cesaro S, Ljungman P, Tridello G, Mikulska M, Wendel L, Styczynski J, et al. New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT. Bone Marrow Transpl. 2023;58:203–8.
doi: 10.1038/s41409-022-01863-8
Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. Transpl Infect Dis J Transpl Soc. 2019;21:e13187.
doi: 10.1111/tid.13187
Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260–e272.
pubmed: 31153807
doi: 10.1016/S1473-3099(19)30107-0
Styczyński J, Tridello G, Xhaard A, Medinger M, Mielke S, Taskinen M, et al. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transpl. 2021;56:1171–9.
doi: 10.1038/s41409-020-01166-w
Richert-Przygonska M, Jaremek K, Debski R, Konieczek J, Lecka M, Dziedzic M, et al. Letermovir prophylaxis for cytomegalovirus infection in children after hematopoietic cell transplantation. Anticancer Res. 2022;42:3607–12.
pubmed: 35790275
doi: 10.21873/anticanres.15848
Kuhn A, Puttkammer J, Madigan T, Dinnes L, Khan S, Ferdjallah A, et al. Letermovir as cytomegalovirus prophylaxis in a pediatric cohort: a retrospective analysis. Transpl Cell Ther. 2023;29:62.e1–62.e4.
doi: 10.1016/j.jtct.2022.10.005
Cheng C-N, Li S-S, Yeh Y-H, Shen C-F, Chen J-S. Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan. J Microbiol Immunol Infect. 2022;55:323–7.
pubmed: 35241378
doi: 10.1016/j.jmii.2022.01.002
Daukshus N, Cirincione A, Siver M, Mathew S, Kunvarjee B, Chan A, et al. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. J Pediatric Infect Dis Soc. https://doi.org/10.1093/jpids/piac017 . (2022).
Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, et al. Epilepsy treatment patterns among patients with tuberous sclerosis complex. J Neurol Sci. 2018;391:104–8.
pubmed: 30103955
doi: 10.1016/j.jns.2018.06.011
Körholz KF, Füller MA, Hennies M, Holterhus M, Hagedorn S, Ahlmann M, et al. Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients. Pediatr Drugs. 2023;25:225–32.
doi: 10.1007/s40272-022-00547-6
Chen TT, David AP, Barthelmess EK, MacBrayne CE. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2023;70:e30608.
pubmed: 37548491
doi: 10.1002/pbc.30608
Pérez Marín M, Decosterd LA, Andre P, Buclin T, Mercier T, Murray K, et al. Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child with Resistant Cytomegalovirus Disease. J Pediatr Infect Dis Soc. 2019;9:96–99.
Chiereghin A, Belotti T, Borgatti EC, Fraccascia N, Piccirilli G, Fois M, et al. Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant. Infect Drug Resist. 2021;14:1185–90.
pubmed: 33790588
pmcid: 8001039
doi: 10.2147/IDR.S296927
Kilgore JT, Becken B, Varga MG, Parikh S, Prasad V, Lugo D, et al. Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient. J Pediatr Infect Dis Soc. 2020;9:486–9.
doi: 10.1093/jpids/piz050
Strenger V, Sperl D, Kubesch K, Donnerer J, Schwinger W, Zach K, et al. Letermovir in paediatric HSCT recipients. J Antimicrob Chemother 2019;74:2820–1.
pubmed: 31139834
doi: 10.1093/jac/dkz218
Carreras E, Dufour C, Mohty M, Kröger N The EBMT Handbook: Hematopoietic stem cell transplantation and cellular therapies. EBMT Handb Hematop Stem Cell Transplant Cell Ther: 2018;Vol III and Vol V:1–702.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.
pubmed: 27682069
doi: 10.1093/cid/ciw668
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis Publ Infect Dis Soc Am. 2019;68:1420–6.
doi: 10.1093/cid/ciy696
Liu LW, Yn A, Gao F, Olson M, Crain M, Abboud R, et al. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. Transpl Cell Ther. 2022;28:510.e1–510.e9.
doi: 10.1016/j.jtct.2022.05.020
Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:34–43.
pubmed: 33657225
pmcid: 8493975
doi: 10.1182/blood.2020009396
Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transpl J Am Soc Transpl Am Soc Transpl Surg. 2021;21:1622–8.
doi: 10.1111/ajt.16450
Robin C, Thiebaut A, Alain S, Sicre de Fontbrune F, Berceanu A, D’Aveni M, et al. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program. Biol Blood Marrow Transpl. 2020;26:978–84.
doi: 10.1016/j.bbmt.2020.01.027
Han G, Stern A, Su Y, Gyurkocza B, Sauter C, Shaffer B, et al. 595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study. Open Forum Infect Dis. 2021;8:S401–S401.
pmcid: 8644769
doi: 10.1093/ofid/ofab466.793
Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, et al. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis Publ Infect Dis Soc Am. 2021;73:1346–54.
doi: 10.1093/cid/ciab298
Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transpl J Am Soc Transpl Am Soc Transpl Surg. 2020;20:1703–11.
doi: 10.1111/ajt.15764
Royston L, Royston E, Masouridi-Levrat S, Chalandon Y, Van Delden C, Neofytos D. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients. Immun, Inflamm Dis. 2021;9:771–6.
pubmed: 33949798
doi: 10.1002/iid3.431
Knoll BM, Seiter K, Phillips A, Soave R. Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. Bone Marrow Transpl. 2019;54:911–2.
doi: 10.1038/s41409-018-0389-9
Jung S, Michel M, Stamminger T, Michel D. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis. 2019;19:388.
pubmed: 31068147
pmcid: 6505103
doi: 10.1186/s12879-019-4016-1
Khawaja F, Batista MV, El Haddad L, Chemaly RF. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr Opin Infect Dis. 2019;32:565–74.
pubmed: 31567572
doi: 10.1097/QCO.0000000000000607
Kim SJ, Huang YT, Foldi J, Lee YJ, Maloy M, Giralt SA, et al. Cytomegalovirus resistance in CD34+-selected hematopoietic cell transplant recipients. Transpl Infect Dis. 2018;20:1–9.
doi: 10.1111/tid.12881
Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159–64.
pubmed: 11830461
doi: 10.1182/blood.V99.4.1159
Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711–9.
pubmed: 19299333
pmcid: 2700312
doi: 10.1182/blood-2008-10-143560
Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, et al. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation. 2016;100:e74–80.
pubmed: 27495775
pmcid: 5030152
doi: 10.1097/TP.0000000000001418
Maffini E, Giaccone L, Festuccia M, Brunello L, Busca A, Bruno B. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2016;9:585–96.
pubmed: 27043241
doi: 10.1080/17474086.2016.1174571
Linder KA, Kovacs C, Mullane KM, Wolfe C, Clark NM, La Hoz RM, et al. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transpl Infect Dis J Transpl Soc. 2021;23:e13687.
doi: 10.1111/tid.13687